Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal
TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while maintaining a Neutral rating.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.35 | 150,000 | $1,402,500.00 | 207,453 | 2026-01-05 | Filing | |
| $10.03 | 100,000 | $1,003,000.00 | 134,693 | 2025-08-20 | Filing | |
| $15.50 | 4,250 | $65,875.00 | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | $52,000.00 | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | $1,053,612.00 | 2,662,180 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.21 | 34,146 | $314,484.66 | 1,013,339 | 2026-01-05 | Filing | |
| $9.21 | 8,508 | $78,358.68 | 98,533 | 2026-01-05 | Filing | |
| $9.21 | 10,397 | $95,756.37 | 101,528 | 2026-01-05 | Filing | |
| $9.21 | 11,903 | $109,626.63 | 121,249 | 2026-01-05 | Filing | |
| $9.21 | 9,515 | $87,633.15 | 87,118 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,010,001 | $116,959,909 | 0% | |
| 2. | 2,192,461 | $19,710,224 | 0.01% | |
| 3. | 859,552 | $7,727,373 | 0% | |
| 4. | Ubs Group AgCALL | 378,184 | $3,399,874 | 0% |
| 5. | 62,642 | $1,940,014 | 0% |
News See All
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
What Makes Intellia Therapeutics (NTLA) an Interesting Investment?
Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here.
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory
We came across a bearish thesis on Intellia Therapeutics, Inc. on X.com by A_May_MD. In this article, we will summarize the bulls’ thesis on NTLA.
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones Trading dropped Intellia Therapeutics, Inc. (NASDAQ:NTLA) from Buy to Hold.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds.
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to Intellia Therapeutics Third Quarter 2025 Financial Results Conference Call. My name is Rocco, and I will be your conference operator today.
Intellia (NTLA) Soars 13% to Fresh High
Earlier this month, Intellia Therapeutics, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
